Splenectomy and/or Bone Marrow Transplantation in the Management of the Wiskott-Aldrich Syndrome: Long-Term Follow-Up of 62 Cases

By Craig A. Mullen, Kathryn D. Anderson, and R. Michael Blaese

This study describes the effects of two major treatment options, splenectomy and/or bone marrow transplantation, on the natural history of the Wiskott-Aldrich (WAS) syndrome. The records of 62 patients with the WAS evaluated at the National Institutes of Health Clinical Center from 1966 to 1992 were reviewed. Nineteen patients were treated with bone marrow transplantation (BMT) and the results were largely dependent on the source of the graft. Twelve of 12 patients receiving HLA-matched sibling marrow achieved satisfactory immunologic and hematologic reconstitution. By contrast, only 2 of 7 patients receiving haploidentical, parental, or matched unrelated marrow survived more than 1 year after BMT. Thirty-nine patients who lacked suitable bone marrow donors early in their course underwent splenectomy for management of their thrombocytopenia; most received prophylactic antibiotics to minimize the risk of sepsis. Nearly all these patients achieved normal platelet counts and the rate of serious bleeding was reduced nearly sevenfold. Median survival in the untransplanted splenectomy group was 25 years, compared with less than 5 years in un splenectomized patients. We conclude that HLA-matched sibling donor BMT is the treatment of choice for patients with WAS and that splenectomy and daily prophylactic antibiotics provide a significant survival advantage to those boys without a matched sibling donor. Splenectomy should probably be used in preference to unmatched BMT until results with alternative donor BMT significantly improve or gene therapy becomes available.

This is a US government work. There are no restrictions on its use.

MATERIALS AND METHODS

The medical records of 69 patients observed for WAS in the Metabolism Branch of the NIH Clinical Center during the years 1966 to 1992 were reviewed. The records of 62 patients were complete enough to include in the analysis. Telephone follow-up interviews were conducted with living patients or their families if they had not visited the NIH Clinical Center in the preceding 18 months. In general, the patients received their primary medical care near their homes and were seen annually at the NIH. The criteria for the diagnosis of WAS (and the number of patients with documented fulfillment of them) included male sex (62 of 62), and the classic triad of thrombocytopenia (62 of 62), eczema (57 of 62), and recurrent infections (39 of 62). Features corroborating the diagnosis included a family history compatible with X-linked transmission (documented in 38 of 62 cases), small platelets (<3 standard deviations [SD] below the mean normal platelet volume; normal range: 6.6 ± 0.8 μm³ SD) present in 30 of 31 evaluated, subnormal IgM levels, low isohemagglutinins, impaired antibody production to polysaccharide antigens, impaired in vitro proliferation to allogeneic cells and soluble antigens, skin test anergy, impaired monocyte-mediated antibody-dependent cytotoxicity, and increased rates of metabolism of serum proteins. Fifty-five of 62 fulfilled the classic diagnostic triad. Of the remaining 7, all had evidence of immune dysfunction, and 5 had a positive family history. The 2 patients lacking a family history had small platelets, which, in our experience, has been a nearly invariant feature of the disorder.

The practice at our center since 1976 has been to recommend BMT for those patients who have had matched sibling donors. Splenectomy has been recommended for those patients without suitable donors who have had platelet counts of less than 50,000/mm³. Splenectomies were performed at the Children's National Medical Center or by surgeons in the patients' home communities. After 1978, daily postsplenectomy prophylactic antibiotics were routinely prescribed. The antibiotic regimens were trimethoprim/sulfamethoxazole (SMX) (6 mg/kg/day of SMX in two divided doses) or amoxicillin (40 mg/kg/day in three divided doses). Intravenous Ig (IVlg) was not routinely administered. Fourteen of the 62 did receive IVlg, usually episodically when infected. Four patients

From the Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, and the Department of Surgery, Children's Hospital of Los Angeles, Los Angeles, CA. Submitted March 1, 1993; accepted July 12, 1993.

Address reprint requests to Craig A. Mullen, MD, PhD, National Institutes of Health, Building 10, Room 4N115, Bethesda, MD 20892.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

This is a US government work. There are no restrictions on its use.

Blood, Vol 82, No 10 (November 15), 1993: pp 2961-2966
received 500 mg/kg every 3 to 4 weeks on a long-term basis. Patients developing fevers over 102°F were advised to immediately seek medical attention including blood cultures and modification of their antibiotic regimen to broaden antimicrobial coverage. For this study sepsis was conventionally defined as an episode of severe illness associated with hemodynamic instability in a bacteremic patient; we have excluded 3 cases of transient bacteremias in 3 febrile patients who were otherwise well. Patients were referred to outside centers for BMT. The 19 transplants were performed at 7 different centers.

Descriptive statistics were calculated by standard methods. Rates for bleeding, sepsis, and death were calculated by dividing the total number of events by the total number of person years at risk. Comparisons were performed by t-tests unless otherwise specified. Other tests included χ² and Kaplan-Meier life table analyses. The life tables plot the proportion of the evaluable study population alive in a given time interval. In calculating this proportion, members of the study population who are alive but have not reached the interval age are censored. Tick marks on the curves represent the last recorded age of the living subjects.

RESULTS

Patient population and changing natural history of WAS. During the period under study, several advances in the treatment of WAS occurred. Table 1 describes our 62 patients and categorizes the group on the basis of BMT and splenectomy. Eleven males underwent BMT as the initial treatment of their WAS and did not undergo splenectomy. Twelve patients underwent neither BMT nor splenectomy. Nine patients were observed during the period before 1978 when we did not recommend splenectomy for WAS patients. Two boys had platelet counts less than 50,000/μL but splenectomy was refused by their parents despite its recommendation. Life table survival analysis for the entire group of 62 patients projected a median survival of 18 years (Fig 1), a significant improvement compared with historical results. Sixteen patients had platelet counts less than 50,000/μL, and twelve developed transfusion-dependent thrombocytopenia (Table 2). The average presplenectomy platelet count was 27,878/μL and after the procedure the platelet count averaged 262,805/μL. In general, the platelet counts became normal within a few days of the splenectomy.

Among patients not receiving transplants, a median survival of 4 years in the group not splenectomized was found, whereas the splenectomy group had a median survival of 25 years (Fig 2).

Splenectomy clearly improved the patients' thrombocytopenia (Table 2). The average presplenectomy platelet count was 27,878/μL and after the procedure the platelet count averaged 262,805/μL. In general, the platelet counts became normal within a few days of the splenectomy.

Many of the patients had experienced clinically significant episodes of bleeding before splenectomy, commonly, gastrointestinal bleeding and intracranial hemorrhage (Table 2). Most had more than two significant hemorrhagic episodes before splenectomy, with an average of 0.45 episodes per person per year. Eight episodes of intracranial hemorrhage resulted in 3 deaths in patients never splenectomized or before their splenectomy. After splenectomy, most were less than 4 years of age. No serious perioperative infections occurred, nor did serious surgical complications; approximately half the patients required no platelet transfusions in the perioperative period. The median age at splenectomy was 3.5 years; 16 patients were 2 years old or younger at the time. Those patients undergoing a splenectomy before 5 years of age did not suffer more serious infections or earlier mortality than those whose spleen was removed at a later age. Twenty-two of the splenectomized patients are alive and are an average of 7.3 years from their splenectomy. Four of these 22 underwent successful BMT some time after removal of their spleen. Seventeen of the patients who underwent splenectomy have died; their average survival after splenectomy was 7.2 years. Four of these patients had received BMT after splenectomy; 3 of them died of transplant-related complications and the other of lymphoma shortly after the BMT.

Fig 1. Survival of patients with WAS. Kaplan-Meier plot of proportion of the entire patient population surviving to a given age in years. Tick marks represent the age of patients still alive.
thrombocytopenic bleeding was reduced to 0.07 episodes per person per year.

However, bleeding was not completely eliminated by splenectomy because patients with WAS are also prone to idiopathic thrombocytopenic purpura (ITP); 14 of our 62 patients developed ITP. Postsplenectomy bleeding was always associated with ITP. In these cases, platelet size remained normal and high levels of platelet-associated IgG were usually present. Seven patients had developed ITP before splenectomy; of these, 6 also had episodes of ITP after splenectomy. Intraplatelet hemorrhage occurred in 2 patients after splenectomy and 2 patients died of bleeding despite splenectomy.

**Postsplenectomy sepsis.** Twenty-seven of the 39 patients in the splenectomy group have experienced an episode of sepsis (Table 3). Twelve have been septic and 5 have died as a result. However, the introduction of routine daily prophylactic antibiotics dramatically reduced the incidence of sepsis. All of the 27 patients not experiencing sepsis received prophylactic antibiotics. Seven of the 12 having postsplenectomy sepsis either never had antibiotics prescribed or discontinued them against medical advice; 3 patients experienced fatal episodes. Every patient who did not receive antibiotics or discontinued antibiotic treatment against medical advice experienced at least one episode of sepsis. Antibiotics did not eliminate the risk of postsplenectomy sepsis; 5 patients experienced sepsis despite taking the drugs, and 2 died as a result. For patients taking prophylactic antibiotics, the annual risk of fatal sepsis was 0.012 per person per year. Table 4 details the causes of death among the 17 patients who died after splenectomy. Sepsis played a role in only 5 of these deaths.

**BMT.** Nineteen patients underwent BMT (Table 5). Eleven patients received BMT without prior splenectomy. Ten of these received HLA-matched sibling grafts and did well. One received a maternal graft and died of severe graft-versus-host disease (GVHD). Eight patients underwent BMT after splenectomy and, as a group, were older than those who received transplants immediately (Table 5). Only

---

**Table 2. Hematologic Effect of Splenectomy**

<table>
<thead>
<tr>
<th></th>
<th>Average ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation platelet count, all patients (n = 57)</td>
<td>28,000 ± 22,918</td>
</tr>
<tr>
<td>Presentation platelet count, splenectomy (n = 33)</td>
<td>27,878 ± 22,489</td>
</tr>
<tr>
<td>Post-splenectomy platelet count (n = 36)</td>
<td>262,805 ± 135,455</td>
</tr>
<tr>
<td>Major bleeding episodes, presplenectomy (n = 33)</td>
<td>2.3 ± 2.2</td>
</tr>
<tr>
<td>Major bleeding rate, presplenectomy</td>
<td>0.45 episodes/yr</td>
</tr>
<tr>
<td>Major bleeding episodes, postsplenectomy (n = 34)</td>
<td>0.5 ± 1.1</td>
</tr>
<tr>
<td>Major bleeding rate, postsplenectomy</td>
<td>0.07 episodes/yr</td>
</tr>
</tbody>
</table>

* Number was sometimes less than the total number of patients undergoing splenectomy (39) because only data known with confidence was used in the calculation of the statistics.
† Four patients had post-splenectomy platelet counts less than 100,000/mL: 25,000, 50,000, 88,000, and 99,000. The 3 with the lowest counts had recurrent ITP and had experienced more bleeding before and after splenectomy than most patients.
‡ Major bleeding episode was one that required medical intervention, such as intracranial hemorrhage, gastrointestinal bleeding, or intractable epistaxis. Rate is average number of episodes per patient year at risk.
§ Significantly greater than presplenectomy count (P < .001).

---

**Table 3. Postsplenectomy Sepsis**

<table>
<thead>
<tr>
<th></th>
<th>Sepsis</th>
<th>Fatal Sepsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibiotics</td>
<td>27</td>
<td>5</td>
</tr>
<tr>
<td>No antibiotics*</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>27</td>
<td>12</td>
</tr>
</tbody>
</table>

Sepsis is conventionally defined as an episode of severe illness associated with hemodynamic instability in a bacteremic patient; we have excluded 3 cases of transient bacteremia in 3 febrile patients who were otherwise well. Differences between groups are statistically significant. For no sepsis versus sepsis comparison, \( \chi^2 = 19.2, df = 1, P < .001; \) for no fatal sepsis versus fatal sepsis comparison, \( \chi^2 = 6.89, df = 1, P < .009. \)

* Five patients never had antibiotics prescribed; 2 patients discontinued antibiotics against medical advice. All experienced episodes of sepsis.
the other had infection complicate end-stage renal insufficiency.

and who did not receive matched sibling grafts, 4 died dur-

the splenectomy-only group. However, cured. Of the

group, patients receiving nonsibling BMT did worse than

of prophylactic antibiotics.

bleeding episodes. The risk of fatal postsplenectomy sepsis

was effectively reduced but not totally eliminated by the use

Postsplenectomy sepsis 5t 6.0 (3.3 to 25.2)
Cancer 5 8.5 (4.1 to 18.1)
BMT 3 8.7, 12.4, 16.6
Hemorrhage/ITP 2 3.1, 4.2
Secondary infection† 2 8.7, 32.9
Autoimmune renal insufficiency 1 32.9
Unknown 1 —

* Age at death in years. Median and range presented when more than
3 cases.
† Three of these patients were not taking prophylactic antibiotics.
‡ Total number of contributing causes (19) exceeds the number of
deaths (17) because in two cases multiple factors contributed to the
patient's death. One patient developed infection during BMT, whereas
the other had infection complicate end-stage renal insufficiency.

2 received matched sibling grafts and these 2 patients were
cured. Of the 6 patients who had a prior splenectomy and
who did not receive matched sibling grafts, 4 died during
or shortly after BMT. One patient died from veno-oc-
cclusive disease, another of acute GVHD, a third failed to
engraft, and the fourth developed chronic GVHD and died
with a lymphoproliferative disorder. Figure 2 compares sur-
vival after BMT for all patients. All patients with matched
sibling donors appear to be long-term survivors, whereas 5
of 7 of those receiving maternal haploidentical or unrelated
matched grafts died shortly after transplantation. As a
group, patients receiving nonsibling BMT did worse than
the splenectomy-only group. However, 3 of the nonsibling
BMT patient deaths occurred in patients with serious pre-
transplant illnesses (liver disease and steroid-dependent ITP
for 2 of the unrelated BMT recipients, and Burkitt's lymph-
oma in remission in the case of 1 patient who had had a
haploidentical BMT).

DISCUSSION

This report describes the long-term evaluation of WAS
patients who underwent splenectomy and/or BMT. The re-
sults corroborate our 1980 report, which proposed that
splenectomy could be an effective management tool in these
boys.8 Splenectomy clearly normalized the platelet count in
nearly all patients and resulted in a reduced incidence of
bleeding episodes. The risk of fatal postsplenectomy sepsis
was effectively reduced but not totally eliminated by the use
of prophylactic antibiotics.

Although the patients' platelet counts were increased by
the procedure, the key question is whether it resulted in
improved survival and/or quality of life. In the absence of a
prospective controlled trial of splenectomy, one must rely
on previously published material on the natural history of
the syndrome. A comprehensive review of 301 cases was
published in 1980 by investigators at the University of Min-
nesota.16 It estimated that for boys born after 1964 (a cohort
similar to ours) average survival was 6.5 years and that 23%
of all deaths in this group resulted from hemorrhage. As a
group, our patients who undergone splenectomy are living
longer. Excluding patients receiving BMT, projected me-
dian survival is 25 years for those with splenectomy and 4
years for those not undergoing splenectomy. In the splene-
tomy group, only 5% have died from hemorrhage, less than
one quarter of the incidence reported in the Minnesota se-
dies. It should be noted that most of the boys not undergoing
splenectomy were followed in the 1970s; it is certainly possi-
ble that changes in supportive care during the 1980's have
contributed to the difference in survival in the splenectomy
patients. However, during this decade there were no dra-
matic improvements in antibiotic efficacy or blood-product
support that we believe account for the survival differences
observed. It is important to note that no stable survival
plateau is achieved, reinforcing the point that, although
splenectomy is useful, it is not curative.

The boys' quality of life has improved with splenectomy.
Without the specter of dangerous thrombocytopenia, they
have had the opportunity to lead normally active lives.
None has had to endure restricted play nor wear protective
headgear. In addition, those who have suffered the frequent
arthralgias and arthritides associated with the syndrome
have been able to use anti-inflammatory agents previously
contraindicated because of their antiplatelet activity. Splen-
ectomy has also made management of later episodes of ITP
easier; ITP-related thrombocytopenia has been briefer and
less profound in the splenectomized patients. Finally, nor-
malization of platelet counts by splenectomy has allowed
patients who later developed malignancies to receive full
therapeutic doses of chemotherapy that would have other-
wise been limited by thrombocytopenia.

The principal concern about splenectomy is that it may
predispose WAS patients to a significantly higher incidence
of fatal sepsis. Five of the 38 patients in our series did die of
sepsis. When we initially recommended splenectomy as a
treatment for WAS and reviewed the relevant literature,9
the critical importance of prophylactic antibiotics in pre-
vting this complication was emphasized. The present
data confirm the importance of our initial recommenda-
tions. Of the 27 patients never experiencing sepsis, all were
regularly receiving prophylactic antibiotics and/or IVIg. By
striking contrast, all 7 of the 7 patients not taking antibiotics
experienced at least one episode of sepsis and 3 of these
patients died of this catastrophic complication. However, it

<table>
<thead>
<tr>
<th>Contributing Factor</th>
<th>No. of Patients</th>
<th>Age at Death*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Postsplenectomy sepsis</td>
<td>5t</td>
<td>6.0 (3.3 to 25.2)</td>
</tr>
<tr>
<td>Cancer</td>
<td>5</td>
<td>8.5 (4.1 to 18.1)</td>
</tr>
<tr>
<td>BMT</td>
<td>3</td>
<td>8.7, 12.4, 16.6</td>
</tr>
<tr>
<td>Hemorrhage/ITP</td>
<td>2</td>
<td>3.1, 4.2</td>
</tr>
<tr>
<td>Secondary infection†</td>
<td>2</td>
<td>8.7, 32.9</td>
</tr>
<tr>
<td>Autoimmune renal insufficiency</td>
<td>1</td>
<td>32.9</td>
</tr>
<tr>
<td>Unknown</td>
<td>1</td>
<td>—</td>
</tr>
</tbody>
</table>

* Age at death in years. Median and range presented when more than 3 cases.
† Three of these patients were not taking prophylactic antibiotics.
‡ Total number of contributing causes (19) exceeds the number of deaths (17) because in two cases multiple factors contributed to the patient's death. One patient developed infection during BMT, whereas the other had infection complicate end-stage renal insufficiency.

---

Table 5. Outcome of BMT in WAS Patients

<table>
<thead>
<tr>
<th>Prior Splenectomy</th>
<th>No. Alive/No. Grafted*</th>
<th>Age†</th>
<th>Alive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sibling</td>
<td>10/10†</td>
<td>0.0</td>
<td>3.6 ± 1.1</td>
</tr>
<tr>
<td>Parental</td>
<td>2/2</td>
<td>1.3</td>
<td>6.9 ± 1.6</td>
</tr>
<tr>
<td>Unrelated</td>
<td>12/12</td>
<td>1.4</td>
<td>5.1 ± 1.2</td>
</tr>
</tbody>
</table>

* Designates number of patients still alive and whether bone marrow donor was an HLA-matched sibling, a parent, or an HLA-matched unre-
lated donor.
† Age at transplant in years (average ± SEM).
‡ Fraction receiving sibling grafts and the fraction alive significantly greater in the no prior splenectomy group (P < .05 by x² analysis).

From www.bloodjournal.org by guest on July 15, 2017. For personal use only.
is also important to note that 2 of 31 splenectomy patients in our series who were taking antibiotics also died of sepsis.

Thus, the use of prophylactic antibiotics after splenectomy substantially reduced, but did not totally eliminate, the risk of sepsis. In our series, the risk of a fatal episode of sepsis in a splenectomized WAS patient taking antibiotics was 0.012 cases per person per year. This compares favorably with the fatal sepsis rate of 0.0025 cases per person per year found in a large series of nonimmunodeficient children after splenectomy.15 A study of patients who underwent splenectomy for Hodgkin’s disease (immunodeficient on the basis of their malignancy and the therapy they received) showed the incidence of sepsis to be 0.0035 cases per person per year.16 A large study of adults undergoing splenectomy for hematologic disorders (72% of whom had nonmalignant diseases) found a rate of 0.0068 cases of sepsis per person per year or 0.0051 sepsis deaths per person per year.19 Other large studies of post-splenectomy sepsis in the general population have estimated sepsis rates of 0.0042 per person per year and fatalities at 0.0008 per person per year.20 WAS patients receiving a splenectomy before the age of 5 years did not suffer more infections than our older patients, unlike the pattern in immunologically normal children. This is likely attributable to the failure of WAS patients as they grow older to normally acquire immunity to organisms with polysaccharide antigens.

However, without prophylaxis, the risk of sepsis is great. All WAS patients failing to receive antibiotics had life threatening infections. Antibiotics must be continued for life; sepsis has been observed in patients in their late 20s, more than 20 years following splenectomy. Fatal infections can occur, even with organisms sensitive in vitro to the antibiotic;21,22 although it is likely that in many such cases the prophylactic antibiotics may slow the pace or diminish the magnitude of the infection. Therefore, it must be emphasized that vigilance for infection must be maintained even when patients faithfully take prophylactic antibiotics. Education of patients and families to immediately seek medical attention when fever occurs despite antibiotics is very important.

The treatment of choice for patients with WAS is matched sibling BMT. All of our patients who received such grafts have survived the procedure and seem to be cured. Others have made similar observations.23 However, most WAS patients do not have a matched sibling donor at the time of their diagnosis. For such patients splenectomy is a useful procedure because it reduces the chances of fatal bleeding. Unlike successful BMT, it does not remove the serious problems of immune deficiency, lymphoid malignancies, or severe autoimmune disease (Table 4). Despite this, the poor outcome seen in the patients who did not receive matched sibling grafts suggests that splenectomy may be safer and more effective than a suboptimal graft. Our observation may be somewhat confounded by the fact that several of the patients receiving such grafts were ill at the time of transplant. However, most others have also reported poor success with haploidentical donors,24-25 although there is one report to the contrary26; we strongly discourage these patients receiving transplants with haploidentical or parental grafts. Our experience with unrelated matched grafts is limited. Others have seen fairly good results with such grafts27 and, in the future as this technology develops, it may be a good alternative for the patient without a matched sibling who is doing poorly with splenectomy alone.

A frequently voiced concern among families is whether splenectomy compromises the success of later BMT, should circumstances change to make a transplant possible. Our splenectomy patients have fared much more poorly in BMT than patients going to BMT without prior splenectomy. However, the non-splenectomized BMT patients were younger, healthier, and much more likely to receive marrow from a completely matched sibling. We believe that these factors rather than the splenectomy account for the difference between the groups.

In summary, our experience with a large group of WAS patients over more than 25 years suggests that, for those WAS patients without suitable bone marrow donors who have platelet counts less than 50,000/μL, splenectomy is effective in treating their thrombocytopenia. Moreover, as long as antibiotic prophylaxis is faithfully continued, the procedure does not add significantly to the risk of fatal infection in these boys but does add to their longevity and quality of life.

ACKNOWLEDGMENT

We thank Dr Fabio Candotti for critical review of the manuscript and Dr Seth Steinberg for statistical advice.

REFERENCES

Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases

CA Mullen, KD Anderson and RM Blaese

Updated information and services can be found at:
http://www.bloodjournal.org/content/82/10/2961.full.html

Articles on similar topics can be found in the following Blood collections

Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints

Information about subscriptions and ASH membership may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml